Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 02:00 ET | Source: Transgene S.A.

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers
April 13, 2026 02:00 ET | Source: Transgene S.A.

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026 01:00 ET | Source: BioVersys

Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)

BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and...
April 12, 2026 19:30 ET | Source: Nxera Pharma

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with...
April 11, 2026 07:00 ET | Source: BioNTech SE

BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs

BioNTech gab heute positive Ergebnisse aus der primären Analyse einer Phase-2-Kohorte mit Trastuzumab Pamirtecan bei HER2+ Gebärmutterkrebs bekannt.
April 11, 2026 07:00 ET | Source: BioNTech SE

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
April 10, 2026 17:02 ET | Source: Replimune, Inc.

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
April 10, 2026 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
April 10, 2026 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
April 09, 2026 16:31 ET | Source: Nouveau Monde Graphite Inc.

NMG Announces US$297 Million Equity Financing Package including US$213 Million Private Placement and US$84 Million Bought Deal Public Offering, Advancing Phase-2 Matawinie Mine toward FID

Canada Growth Fund, the Government of Québec, through Investissement Québec, and Eni S.p.A., commit to an aggregate US$213 million equity investment, to support the advancement of NMG’s Phase-2...